You just read:

S*BIO's Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma

News provided by

S*BIO Pte Ltd

Dec 06, 2010, 08:00 EST